Demystify statistical significance - Time to move on from the p value to bayesian analysis

Journal of the National Cancer Institute

Volumn 103, Issue 1, 2011, Pages 2-3

  Lee, J Jack ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAYES THEOREM; DEMYSTIFY STATISTICAL SIGNIFICANCE; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HAZARD RATIO; NULL HYPOTHESIS; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG APPROVAL; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; ODDS RATIO; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78651290757     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq493     Document Type: Editorial

References (19)

1. The United Nations Statistics Division. World Statistics Day 2010. 2010. http://unstats.un.org/unsd/wsd/Default.aspx. Accessed October 26, 2010.
2. Ashby D, Smith AFM. Evidence-based medicine as Bayesian decision-making. Stat Med. 2000;19(23):3291-3305.
3. Greenhalgh T. How to Read a Paper: The Basics of Evidence-Based Medicine. Chichester, UK: John Wiley & Sons Ltd; 2010.
4. Ocana A, Tannock IF. When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst. 2011;103(1):16-20.
5. Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med. 1999;130(12):995-1004.
6. Goodman SN. Toward evidence-based medical statistics. 2: The Bayes factor. Ann Intern Med. 1999;130(12):1005-1013.
7. Wagenmakers E-J. A practical solution to the pervasive problems of p values. Psychon Bull Rev. 2007;14(5):779-804.
8. Wijeysundera DN, Austin PC, Hux JE, Beattie WS, Laupacis A. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. J Clin Epidemiol. 2009;62(1):13-21.
9. Berry DA. Statistics: A Bayesian Perspective.Pacifc Grove, CA: Duxbury Press; 1996.
10. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. West Sussex, UK: John Wiley & Sons Ltd; 2004.
11. Goodman SN. Introduction to Bayesian methods I: measuring the strength of evidence. Clin Trials. 2005;2(4):282-290.
12. Louis TA. Introduction to Bayesian methods II: fundamental concepts. Clin Trials. 2005;2(4):291-294.
13. Berry DA. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis. Clin Trials. 2005;2(4): 295-300.
14. Berry DA. A guide to drug discovery: Bayesian clinical trials. Nat Rev Drug Discov. 2006;5(1):27-36.
15. Biswas S, Liu DD, Lee JJ, Berry DA. Bayesian clinical trials at the University of Texas M.D. Anderson Cancer Center. Clin Trials. 2009;6(3): 205-216.
16. Berry SM, Carlin BP, Lee JJ, Müller P. Bayesian Adaptive Methods for Clinical Trials.Boca Raton, FL: Chapman & Hall; 2010.
17. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer- a step toward personalized medicine. Clin Trials. 2008;5(3):181-193.
18. Lee JJ, Xuemin Gu, Suyu Liu. Bayesian adaptive randomization designs for targeted agent development. Clin Trials. 2010;7(5):584-596.
19. Held L. A nomogram for P values. BMC Med Res Methodol. 2010;10:21.